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LETTER TO THE EDITOR
Time for a general approval of growth 
hormone treatment in adults with Prader–Willi 
syndrome
Charlotte Höybye1, Anthony J. Holland2 and Daniel J. Driscoll3*  on behalf of The Clinical and Scientific 
Advisory Board of The International Prader-Willi Syndrome Organisation
Abstract 
Prader-Willi syndrome (PWS) is a complex, multi-system, neurodevelopmental disorder characterised by neonatal 
muscular hypotonia, short stature, high risk of obesity, hypogonadism, intellectual disabilities, distinct behavioural/
psychiatric problems and abnormal body composition with increased body fat and a deficit of lean body mass. 
Growth hormone (GH) deficiency and other hormone deficiencies are common due to hypothalamic dysfunction. In 
children with PWS GH treatment has been widely demonstrated to improve body composition, normalise height and 
improve psychomotor development. In adults with PWS, GH’s main effects are to maintain normal body structure and 
metabolism. The positive effects of GH treatment on body composition, physical fitness and beneficial effects on car-
diovascular risk markers, behaviour and quality of life in adults with PWS are also well established from several studies. 
GH treatment is approved for treatment of children with PWS in many countries, but until recently not as a treatment 
in young adults in the transition period or for adults in general. In this commentary we want to draw attention to the 
uneven global use of GH treatment, specifically in adults with PWS, and advocate for GH treatment to be approved 
internationally, not just for children, but also for adults with PWS and based only on the diagnosis of genetically con-
firmed PWS.
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In the article “Three years of growth hormone treatment 
in young adults with Prader–Willi syndrome: sustained 
positive effects on body composition” Damen and col-
leagues [1] demonstrated that continued treatment with 
growth hormone (GH) in young adults with Prader–Willi 
syndrome (PWS) after attainment of final height main-
tained the improved body composition obtained with GH 
treatment during childhood. Following the proven suc-
cess of GH treatment for children and some adults with 
PWS, it is time to expand upon the limited treatment 
options for adults with this condition and push for wide-
spread approval of GH use across all ages.
PWS is a rare multi-system neurodevelopmental disor-
der caused by lack of expression of genes in the paternally 
inherited chromosomal region 15q11.2-q13 [2]. PWS 
is characterised by neonatal muscular hypotonia, short 
stature, a high risk for obesity, hypogonadism, intellec-
tual disabilities, distinct behavioural/psychiatric prob-
lems and abnormal body composition with increased 
body fat and a deficit of lean body mass. GH deficiency 
(GHD) and other hormone deficiencies are common due 
to hypothalamic dysfunction [2, 3]. Furthermore, differ-
ent nutritional phases have been described from feeding 
difficulties and failure to thrive in infancy, to progres-
sive hyperphagia with high risk of severe obesity from 
childhood to adulthood [4]. Morbidity is increased and 
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complications of obesity, such as respiratory and cardio-
vascular diseases, are major causes of death [2, 3].
The treatment options for adults with PWS are very 
limited and consist of a lifelong and environmentally con-
trolled restricted energy intake, as well as regular physi-
cal activity and replacement of hormone deficiencies. 
For many years GH treatment in children with PWS has 
been approved in the USA, Europe and some other coun-
tries around the globe without the need for GH provo-
cation testing, whereas in adults this approval has been 
obtained only recently and in only a few countries. In this 
commentary we want to draw attention to the uneven 
global distribution of approval for, and use of, GH as a 
treatment specifically for adults with PWS as reported to 
The International Prader–Willi Syndrome Organisation, 
and advocate for GH treatment to be approved interna-
tionally for adults with PWS and, for reasons we explain 
below, based only on the diagnosis of PWS.
In typically developing adults, GH no longer causes 
growth but it helps maintain normal body structure 
and metabolism, including keeping blood glucose levels 
within set levels. Treatment with GH in children with 
GHD started in the late 1950s. Assessment of efficacy 
consisted of measurement of height and body propor-
tions, but in the late 1980s, when recombinant human 
GH became available, interest in the metabolic effects 
of GH intensified. The typical clinical picture of severe 
GHD in adults was described, and included abnormal 
body composition, fatigue, decreased physical activity, an 
adverse cardiovascular risk profile independent of obe-
sity, and a reduced quality of life. Since the 1990′s adults, 
who have severe GHD according to specified diagnostic 
criteria, have been treated with GH and several studies 
have documented that GH improves body composition, 
cardiovascular risk factors and quality of life with few 
side effects [5].
Adults with PWS share similarities with non-PWS 
adults with GHD in particular regarding body composi-
tion given their reduced lean body mass and increased 
fat mass. Profound GHD, defined according to existing 
diagnostic criteria, has been demonstrated in up to 55% 
of adults with PWS [6, 7]. However, most GH stimula-
tion tests measure the secretion of GH from the pituitary. 
This can lead to a false normal GH responses in patients 
whose GHD is of hypothalamic origin, such as in people 
with PWS. In addition, the increased amount of adipose 
tissue can confound the results. Levels of insulin growth 
factor I (IGF-I), the GH dependent growth factor, are 
low in the majority [6] and IGF-I levels are affected by 
nutritional status, presence of hypogonadism, spontane-
ous GH secretion and several other factors, which have 
not been fully investigated in PWS. Nevertheless, the 
hypothalamic dysfunction is permanent by nature of this 
condition, and therefore affected adults are expected to 
have the same hormone deficiencies as seen in the chil-
dren. Thus, GHD is accepted as part of the phenotype 
PWS and due to all factors that might potentially affect 
the results of GH test in different directions, GH stimula-
tion tests are of questionable value and are not of clinical 
relevance in this group of patients. Of note is the fact that 
GH stimulation tests might be cumbersome and difficult 
to perform in patients with PWS. Reasons for this include 
the presence of behavioural issues and the potential for 
the patient not cooperating. Furthermore, dependent on 
the amount of subcutaneous fat, blood sampling can be 
very difficult. Stimulation of GH secretion with insulin 
hypoglycemia is unpleasant and for an insulin resistant 
patient it might be difficult to obtain hypoglycemia.
GH treatment in children with PWS started in the 
1990′s. Remarkable effects on height and body composi-
tion were observed and GH treatment in children with 
PWS was approved by the U.S. Food and Drug Admin-
istration and the European Medicines Agency independ-
ent of GH secretory status. The positive effects of GH 
treatment in adults with PWS are also well-known from 
several studies, as well as the recent article by Damen 
and colleagues [1, 6, 7]. In 2012 a meta-analysis of eight 
studies including 134 adults with PWS treated with GH 
showed that body composition improved with a weighted 
mean increase in LBM of 2.4 kg [95% CI 1.31;3.49] and 
a weighted mean reduction in body fat of − 2.9 kg [95% 
CI − 3.90; − 1.91] [8]. This positive effect on body com-
position was reported in all studies and has been con-
firmed in later studies, including long-term studies, all 
showing similar results [9–11]. However, BMI, waist cir-
cumference and waist-hip ratio were unchanged prob-
ably because the abnormal body composition in PWS 
is not accurately reflected by these measurements. The 
beneficial effect of GH on body composition has also 
been proven indirectly by the observation of impaired 
body composition after GH treatment was discontin-
ued. Thus, 12 months of discontinuation of GH resulted 
in a 22% increase in body fat in young adults [12] and 
to an increase in visceral adipose tissue in adults from 
25.2 ± 14.5 to 48.0 ± 26.1  cm2 (p = 0.024) [13]. In line 
with these findings, motor skills were impaired 6 months 
after GH treatment was discontinued [14]. Conversely, 
improvements in physical activity, as a result of the 
improved body composition resulting from GH treat-
ment, have been observed. Using treadmill and acceler-
ometers, exercise intensity was found to improve 16% 
after 6  months and 19% after 12  months of GH treat-
ment in adults with PWS. [15]. Long-term GH treatment 
increased muscle strength by 13% and exercise endurance 
by 17% [16] and peak expiratory flow (PEF) by 12% [9]. 
Low bone mineral density and an increased frequency of 
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fractures are frequently reported in adults with PWS. At 
present, it is not known for certain whether the low BMD 
is caused by impaired growth hormone secretion, low 
levels of sex-steroids, low muscular activity, low intake of 
calcium and D-vitamin or a combination of some or all of 
these things. Recently GH treatment in young adults with 
PWS did not improve BMD, probably because of a rela-
tively short period of treatment and also the patients did 
not systematically receive sex hormone replacement [17]. 
On the other hand, in adults bone formation markers 
increased with GH treatment, whereas resorption mark-
ers did not change [18]. Moreover, it has been shown that 
GH treatment improved mental and cognitive function 
[14] and other studies have reported a better quality of 
life with GH treatment although caregivers/relatives were 
less optimistic in another study [19]. A significant impair-
ment in psychosocial function in adults was noted when 
GH treatment was discontinued [14], while no change 
was seen in young adults [20]. Nevertheless, in PWS an 
integrated assessment of the patient is crucial in both 
considering a decision on the start of and in the evalua-
tion of the effect of GH treatment, as also concluded in 
a large, recent study of 140 young adults with PWS [21].
In summary, the studies, including randomized con-
trolled trials, have shown normalisation of IGF-I lev-
els, increase in lean body mass, decrease in body fat, 
improved physical fitness, and beneficial effects on car-
diovascular risk markers, and on behaviour and quality of 
life. These benefits have been observed in the absence of 
any relationship to levels of stimulated GH secretion. In 
addition, one study has clearly demonstrated that discon-
tinuation of GH treatment at completion of growth in the 
transition period to adulthood, results in deterioration 
in body composition, and in endocrine and metabolic 
markers. These then normalize after resuming GH treat-
ment [8].
While there are clear benefits one important caveat is 
the fact that GH is administered as daily subcutaneous 
injections. From our experience most adults do not man-
age the GH injections themselves, and supervision of the 
injection is needed. This implies a burden on the caregiv-
ers, but in the future this situation is likely to improve 
with the once weekly GH injections, which also have 
the potential to improve compliance [22]. Side effects to 
GH treatment in PWS were transient and included mild 
peripheral oedema, muscle pain and headache, similar 
to reports from other patient groups treated with GH. 
No worsening in scoliosis or sleep apnoea and no wors-
ening or induction of diabetes mellitus were noted [7]. 
However, one of the physiological effects of GH is to 
increase glucose. An increase in glucose levels is there-
fore expected. For this reason, uncontrolled diabetes 
mellitus is a contraindication to GH treatment [6]. In 
the longer term the improvement in body composition 
achieved by GH treatment with the addition of the drugs 
being developed for appetite control might together lead 
to a substantial decrease in the risk of developing diabe-
tes mellitus.
The incidence of psychoses in adults with PWS is high, 
particularly in those with the maternal uniparental dis-
omy 15 (UPD) genetic type, and the presence of severe 
and active psychiatric illness is a contraindication to 
starting GH treatment at that point in time, but once the 
mental state is stabilized treatment with GH should be 
considered [6]. If the person is being treated with psy-
chiatric medications the starting of GH may affect the 
metabolism of the medication and regularly psychiatric 
evaluation may be indicated for up to six months after 
GH is started.
PWS is a multi-system disorder and strict environmen-
tal control of food and regular physical activity remain 
the core interventions recommended for adults with 
PWS. The issue of GH treatment for adults is of signifi-
cant concern to the PWS community. In fact, it was the 
single most-commonly asked question at the awareness 
booth hosted by the International Prader-Willi Syn-
drome Organisation (IPWSO) at the European Society of 
Paediatric Endocrinology meeting in 2019 and was also 
raised as a query at the European Congress of Endocri-
nology meeting in 2019. We argue that GH treatment, 
with its many beneficial effects and few side effects, offers 
an opportunity to relieve some of the adverse effects of 
PWS in adults. Given the reasons for GHD in people 
with PWS a different interpretation of test and treatment 
results from that in the typical population with GHD is 
in our opinion necessary. GH treatment is approved for 
treatment of children with PWS in many countries, but 
until recently not as a treatment in young adults in the 
transition period or for adults in general. The fact that 
GH treatment is now approved for adults with PWS in 
a few countries is therefore an important milestone. GH 
has an important role in optimisation of care in people 
with PWS, and we advocate for approval for continuing 
GH treatment in young adults with PWS based on the 
genetic diagnosis of PWS without testing of GH secre-
tion. We also propose GH replacement should be offered 
to older adults with genetically confirmed PWS who did 
receive GH during childhood, but it was stopped when 
they reached adulthood, as well as those adults who 
never received GH during childhood. Hopefully we will 
see that soon.
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